RT Journal Article
SR Electronic
T1 Interim results from comparison of immune responses elicited by an inactivated and a vectored SARS-CoV-2 vaccine in seronegative and seropositive participants in India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.03.22284082
DO 10.1101/2023.01.03.22284082
A1 Mangaiarkarasi Asokan
A1 Roshni Florina Joan
A1 Sudhir Babji
A1 Girish Dayma
A1 Prajitha Nitheesh
A1 Vinutha Subrahmanyam
A1 Archana Pandey
A1 Girish Malagi
A1 Pooja Arya
A1 Vibhuti Mahajan
A1 Jayateerth Bhavikatti
A1 Ketakee Pawar
A1 Aishwarya Thorat
A1 Priyanki Shah
A1 Ramakrishna B Goud
A1 Bishnudeo Roy
A1 Shon Rajukutty
A1 Sushil Immanuel
A1 Dhiraj Agarwal
A1 Sankhanil Saha
A1 Akshatha Shivaraj
A1 Patricia Panikulam
A1 Rajeshwari Shome
A1 Shah-E-Jahan Gulzar
A1 Anusmrithi U Sharma
A1 Ajinkya Naik
A1 Shruti Talashi
A1 Madhuri Belekar
A1 Ritu Yadav
A1 Poornima Khude
A1 V Mamatha
A1 S Sudarshan
A1 Urmila Deshmukh
A1 Chinmayee Bhise
A1 Manjiri Joshi
A1 Leeberk Raja Inbaraj
A1 Sindhulina Chandrasingh
A1 Aurnab Ghose
A1 Colin Jamora
A1 Anandi S Karumbati
A1 Varadharajan Sundaramurthy
A1 Avita Johnson
A1 Naveen Ramesh
A1 Nirutha Chetan
A1 Chaitra Parthiban
A1 Asma Ahmed
A1 Srabanti Rakshit
A1 Vasista Adiga
A1 George D’souza
A1 Vinay Rale
A1 Carolin Elizabeth George
A1 Jacob John
A1 Anand Kawade
A1 Akanksha Chaturvedi
A1 Anu Raghunathan
A1 Mary Dias
A1 Anand Bhosale
A1 Padinjat Raghu
A1 LS Shashidhara
A1 Annapurna Vyakarnam
A1 Vineeta Bal
A1 Gagandeep Kang
A1 Satyajit Mayor
YR 2023
UL http://medrxiv.org/content/early/2023/01/05/2023.01.03.22284082.abstract
AB Background There are limited global data on head-to-head comparisons of vaccine platforms assessing both humoral and cellular immune responses, stratified by pre-vaccination serostatus. The COVID-19 vaccination drive for the Indian population in the 18 to 45-year age-group began in April 2021 when seropositivity rates in the general population were rising due to the Delta wave in April-May 2021.Methods Between 30 June 2021 and 28 January 2022, we enrolled 691 participants in the 18-45 age group across 4 clinical sites in India. In this non-randomized and laboratory blinded study, participants received either two doses of Covaxin® 4 weeks apart or two doses of Covishield™ 12 weeks apart per the national vaccination policy. The primary outcome was the seroconversion rate and the geometric mean titer (GMT) of antibodies against the SARS-CoV-2 spike and nucleocapsid proteins. The secondary outcome was the frequency of cellular immune responses pre- and post-vaccination.Findings When compared to pre-vaccination baseline, both vaccines elicited statistically significant seroconversion and binding antibody levels in both seronegative and seropositive individuals. In the per-protocol cohort, Covishield™ elicited higher antibody responses than Covaxin® as measured by seroconversion rate (98.3% vs 74.4%, p<0.0001 in seronegative individuals; 91.7% vs 66.9%, p<0.0001 in seropositive individuals) as well as by anti-spike antibody levels against the ancestral strain (GMT 1272.1 vs 75.4 BAU/ml, p<0.0001 in seronegative individuals; 2089.07 vs 585.7 BAU/ml, p<0.0001 in seropositive individuals). Not all sites recruited at the same time, therefore site-specific immunogenicity was impacted by the timing of vaccination relative to the Delta and Omicron waves. Surrogate neutralizing antibody responses against variants-of-concern were higher in Covishield™ recipients than in Covaxin® recipients and in seropositive than in seronegative individuals after both vaccination and asymptomatic Omicron infection. T cell responses are reported from only one of the four site cohorts where the vaccination schedule preceded the Omicron wave. In seronegative individuals, Covishield™ elicited both CD4+ and CD8+ spike-specific cytokine-producing T cells whereas Covaxin® elicited mainly CD4+ spike-specific T cells. Neither vaccine showed significant post-vaccination expansion of spike-specific T cells in seropositive individuals.Interpretation Covishield™ elicited immune responses of higher magnitude and breadth than Covaxin® in both seronegative individuals and seropositive individuals, across cohorts representing the pre-vaccination immune history of the majority of the vaccinated Indian population.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2021/09/036258Funding StatementThe project was fully supported by CSR funding from Hindustan Unilever Limited (HUL) and Unilever India Pvt. Ltd. (UIPL) and facilitated by the Office of the Principal Scientific Advisor (Government of India).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee/IRB of Bangalore Baptist, National Centre for Biological Sciences, Institute for Stem Cell Science and Regenerative Medicine, Indian Institute of Science Education and Research-Pune, Symbiosis University Hospital and Research Centre-Symbiosis Medical College for Women-Symbiosis School of Biological Sciences-Symbiosis International (Deemed University), King Edward Memorial Hospital and Research Centre, National Chemical Laboratory and St. Johns Research Institute gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors